USPTO serial 90431302
ARCE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SCHMIDT, JOHN JOSEPH
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ARCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Zhi Dong
Zhi Dong HAMRE, SCHUMANN, MUELLER & LARSON, P.C.45 SOUTH SEVENTH STREET, SUITE 2700MINNEAPOLIS, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for medical purposes, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological preparations for veterinary purposes for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological tissue cultures for medical purposes, namely, human blood samples, human allograft tissues, human umbilical cord blood and human induced pluripotent stem cells (iPSCs) from somatic cells; biological tissue cultures for veterinary purposes, namely, animal blood samples, tumors and allograft tissues; blood for medical purposes; cultures of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical purposes, namely, chemical and biological reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; pharmaceuticals, namely, drugs for medical purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; enzymes for medical purposes; enzymes for veterinary purposes; immunostimulants; medicinal infusions for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for human purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for veterinary purposes, namely, for veterinary cancers; preparations of microorganisms for medical or veterinary use, namely, cultures of bacteria and viruses for medical or veterinary use; pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceutical preparations, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals in the nature of pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; transplants comprised of living cells, namely, genetically engineered tissues for medical and transplant purposes; genetically engineered cells for medical purposes, specifically for transplantation purposes; vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 8, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 8, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 22, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 22, 2025 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Apr 21, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 23, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jan 23, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 24, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 19, 2024 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 19, 2024 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 19, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 2, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 31, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 31, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 31, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 29, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 27, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 27, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 27, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 22, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 18, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 18, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 18, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 4, 2022 | NOAC | CORRECTED NOA E-MAILED | — |
| Nov 3, 2022 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Nov 2, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 20, 2022 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Oct 20, 2022 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Aug 2, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 23, 2022 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jan 7, 2022 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 14, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 14, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 24, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 10, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 8, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 6, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 6, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 6, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 1, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 24, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 2, 2021 | NWAP | NEW APPLICATION ENTERED | — |